In the subgroup analysis, this survival benefit was confirmed for the patients who were male, of any age, ECOG = 0, VP1 + VP2 thrombus, single tumor, tumor size > 5 cm, or AFP > 400 ng/mL, Thus, iodine-125 implantation in PVBTT was an effective supplementary method to TACE in treatment of patients with advanced HCC. Here, AFP is linked to neoplasm.